Advertisement

Management of Skin Sarcomas

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mentzel T.
        Cutaneous mesenchymal tumours: an update.
        Pathology. 2014; 46: 149-159
        • Fiore M.
        • Miceli R.
        • Mussi C.
        • et al.
        Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate.
        J Clin Oncol. 2005; 23: 7669-7675
        • Goldblum J.R.
        • Reith J.D.
        • Weiss S.W.
        Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up.
        Am J Surg Pathol. 2000; 24: 1125-1130
        • Mendenhall W.M.
        • Zlotecki R.A.
        • Scarborough M.T.
        Dermatofibrosarcoma.
        Protuberans Cancer. 2004; 101: 2503-2508
      1. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 3; 100-103). https://publications.iarc.fr/588..
        Soft Tissue and Bone Tumours. 2020;
      2. Website. Website. 13. National Comprehensive Cancer Network. Dermatofibrosarcoma Protuberans (Version 1.2020).
        (Avaiable at:) (Accessed Sept 10, 2021)
        • Decanter G.
        • Stoeckle E.
        • Honore C.
        • et al.
        Watch and wait approach for re-excision after unplanned yet macroscopically complete excision of extremity and superficial truncal soft tissue sarcoma is safe and does not affect metastatic risk or amputation rate.
        Ann Surg Oncol. 2019; 26: 3526-3534
        • Gronchi A.
        • Miah A.B.
        • Dei Tos A.P.
        • et al.
        Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2021; 32: 1348-1365
        • Saiag P.
        • Grob J.-J.
        • Lebbe C.
        • et al.
        Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline.
        Eur J Cancer. 2015; 51: 2604-2608
        • van Houdt W.J.
        Margins in DFSP Reconsidered: Primum Non Nocere.
        Ann Surg Oncol. 2020; 27: 634-636
        • Ballo M.T.
        • Zagars G.K.
        • Pisters P.
        • et al.
        The role of radiation therapy in the management of dermatofibrosarcoma protuberans.
        Int J Radiat Oncol Biol Phys. 1998; 40: 823-827
        • Ugurel S.
        • Mentzel T.
        • Utikal J.
        • et al.
        Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
        Clin Cancer Res. 2014; 20: 499-510
        • Huis In ’t Veld E.A.
        • van Coevorden F.
        • et al.
        Outcome after surgical treatment of dermatofibrosarcoma protuberans: Is clinical follow-up always indicated?.
        Cancer. 2019; 125: 735-741
        • Albores-Saavedra J.
        • Schwartz A.M.
        • Henson D.E.
        • et al.
        Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007.
        Ann Diagn Pathol. 2011; 15: 93-97
        • Pawlik T.M.
        • Paulino A.F.
        • McGinn C.J.
        • et al.
        Cutaneous angiosarcoma of the scalp: a multidisciplinary approach.
        Cancer. 2003; 98: 1716-1726
        • Lim S.Z.
        • Ong K.W.
        • Tan B.K.T.
        • et al.
        Sarcoma of the breast: an update on a rare entity.
        J Clin Pathol. 2016; 69: 373-381
        • Guadagnolo B.A.
        • Zagars G.K.
        • Araujo D.
        • et al.
        Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp.
        Head Neck. 2011; 33: 661-667
        • Adem C.
        • Reynolds C.
        • Ingle J.N.
        • et al.
        Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature.
        Br J Cancer. 2004; 91: 237-241
        • Abraham J.A.
        • Hornicek F.J.
        • Kaufman A.M.
        • et al.
        Treatment and outcome of 82 patients with angiosarcoma.
        Ann Surg Oncol. 2007; 14: 1953-1967
        • McGowan T.S.
        • Cummings B.J.
        • O’Sullivan B.
        • et al.
        An analysis of 78 breast sarcoma patients without distant metastases at presentation.
        Int J Radiat Oncol Biol Phys. 2000; 46: 383-390
        • Fields R.C.
        • Aft R.L.
        • Gillanders W.E.
        • et al.
        Treatment and outcomes of patients with primary breast sarcoma.
        Am J Surg. 2008; 196: 559-561
        • Gutman H.
        • Pollock R.E.
        • Ross M.I.
        • et al.
        Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience.
        Surgery. 1994; 116: 505-509
        • Stewart F.W.
        • Treves N.
        Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica.
        Cancer. 1948; 1: 64-81
        • Taghian A.
        • de Vathaire F.
        • Terrier P.
        • et al.
        Long-term risk of sarcoma following radiation treatment for breast cancer.
        Int J Radiat Oncol Biol Phys. 1991; 21: 361-367
        • Brady M.S.
        • Garfein C.F.
        • Petrek J.A.
        • et al.
        Post-treatment sarcoma in breast cancer patients.
        Ann Surg Oncol. 1994; 1: 66-72
        • Berebichez-Fridman R.
        • Deutsch Y.E.
        • Joyal T.M.
        • et al.
        Stewart-treves syndrome: a case report and review of the literature.
        Case Rep Oncol. 2016; 9: 205-211
        • Woodward A.H.
        • Ivins J.C.
        • Soule E.H.
        Lymphangiosarcoma arising in chronic lymphedematous extremities.
        Cancer. 1972; 30: 562-572
        • Grobmyer S.R.
        • Daly J.M.
        • Glotzbach R.E.
        • et al.
        Role of surgery in the management of postmastectomy extremity angiosarcoma (Stewart-Treves syndrome).
        J Surg Oncol. 2000; 73: 182-188
        • Kaufmann T.
        • Chu F.
        • Kaufman R.
        Post-mastectomy lymphangiosarcoma (Stewart-Treves syndrome): report of two long-term survivals.
        Br J Radiol. 1991; 64: 857-860
        • Huis In ’t Veld E.A.
        • Grünhagen D.J.
        • et al.
        Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.
        Eur J Cancer. 2017; 85: 114-121
        • Lans T.E.
        • de Wilt J.H.W.
        • van Geel A.N.
        • et al.
        Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable sSewart-Treves lymphangiosarcoma.
        Ann Surg Oncol. 2002; 9: 1004-1009
        • Bousquet G.
        • Confavreux C.
        • Magné N.
        • et al.
        Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network.
        Radiother Oncol. 2007; 85: 355-361
        • Miller K.
        • Goodlad J.R.
        • Brenn T.
        Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma.
        Am J Surg Pathol. 2012; 36: 1317-1326
        • Beer T.W.
        • Drury P.
        • Heenan P.J.
        Atypical fibroxanthoma: a histological and immunohistochemical review of 171 cases.
        Am J Dermatopathol. 2010; 32: 533-540
        • Cesinaro A.M.
        • Gallo G.
        • Tramontozzi S.
        • et al.
        Atypical fibroxanthoma and pleomorphic dermal sarcoma: a reappraisal.
        J Cutan Pathol. 2021; 48: 207-210
        • Soleymani T.
        • Tyler Hollmig S.
        Conception and management of a poorly understood spectrum of dermatologic neoplasms: atypical fibroxanthoma, pleomorphic dermal sarcoma, and undifferentiated pleomorphic sarcoma.
        Curr Treat Options Oncol. 2017; 18: 50
        • Ang G.C.
        • Roenigk R.K.
        • Otley C.C.
        • et al.
        More than 2 decades of treating atypical fibroxanthoma at mayo clinic: what have we learned from 91 patients?.
        Dermatol Surg. 2009; 35: 765-772
        • Griewank K.G.
        • Schilling B.
        • Murali R.
        • et al.
        TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas.
        Mod Pathol. 2014; 27: 502-508
        • Phelan P.S.
        • Rosman I.S.
        • Council M.L.
        Atypical Fibroxanthoma: the washington university experience.
        Dermatol Surg. 2019; 45: 1450-1458
        • Klein S.
        • Quaas A.
        • Noh K.-W.
        • et al.
        Integrative analysis of pleomorphic dermal sarcomas reveals fibroblastic differentiation and susceptibility to immunotherapy.
        Clin Cancer Res. 2020; 26: 5638-5645
        • Svarvar C.
        • Böhling T.
        • Berlin O.
        • et al.
        Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group.
        Cancer. 2007; 109: 282-291
        • Massi D.
        • Franchi A.
        • Alos L.
        • et al.
        Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases.
        Histopathology. 2010; 56: 251-262
        • Wong G.N.
        • Webb A.
        • Gyorki D.
        • et al.
        Cutaneous leiomyosarcoma: dermal and subcutaneous.
        Australas J Dermatol. 2020; 61: 243-249
        • Wellings E.P.
        • Tibbo M.E.
        • Rose P.S.
        • et al.
        Treatment outcome of superficial leiomyosarcoma.
        J Surg Oncol. 2021; 123: 127-132
        • Kraft S.
        • Fletcher C.D.M.
        Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous “leiomyosarcoma.
        Am J Surg Pathol. 2011; 35: 599-607
        • Zacher M.
        • Heppt M.V.
        • Brinker T.J.
        • et al.
        Primary leiomyosarcoma of the skin: a comprehensive review on diagnosis and treatment.
        Med Oncol. 2018; 35: 135